Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Thyroid hormone supplementation for patients on hemodialysis

Official title: A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

Run by University of California, Irvine · NCT03977207 · Data updated 2026-11-12

This study is testing if a thyroid hormone pill can help people on hemodialysis with mild thyroid issues feel better and improve their heart health.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment336 (estimated)
SponsorUniversity of California, Irvine
Academic / other
Locations1 site (Orange, California)
StatusRecruiting
StartedJuly 20, 2020
Main results expectedNovember 30, 2025
Study endsNovember 30, 2025
Registry record updatedSeptember 8, 2025
Trial IDNCT03977207 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-75 who have been on hemodialysis for at least four weeks and have elevated TSH levels between 3.0-10.0 mIU/L.

Probably not a fit

Patients currently receiving thyroid hormone treatment, those with certain cardiovascular conditions, or those with a life expectancy of less than six months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of levothyroxine, a thyroid hormone, on hemodialysis patients who have high-normal or subclinical hypothyroidism. The study aims to determine whether levothyroxine can improve health-related quality of life, cardiovascular outcomes, and metabolic effects in this population. It will involve a randomized, double-blind, placebo-controlled design with 336 participants receiving either the medication or a placebo. The trial will assess various health metrics, including physical performance and cardiovascular function, to evaluate the efficacy of thyroid hormone replacement.

Why it matters

Potential benefit: If successful, this study could enhance the quality of life and cardiovascular health for hemodialysis patients suffering from hypothyroidism.

How similar studies have gone: While there is limited data on the efficacy of levothyroxine in hemodialysis patients, previous studies have shown associations between elevated TSH levels and adverse health outcomes, indicating a potential for significant findings in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-75 years old
* Received hemodialysis at least four weeks
* Have two consecutive thyrotropin (TSH) levels \>3.0-10.0mIU/L during the screening period
* Have normal free thyroxine (FT4) levels
* Have ability to provide written informed consent

Exclusion Criteria:

* Active treatment with thyroid hormone supplementation or anti-thyroid medications
* Active receipt of dialysis
* Prior kidney transplantation
* Life expectancy less than six months
* Active malignancy or prior thyroid malignancy
* Active pregnancy or planning a pregnancy
* Active coronary ischemia or atrial fibrillation (evaluated by EKG)
* Active congestive heart failure exacerbation
* Osteoporosis
* Weight in excess of 450 lbs.
* Hyperthyroidism as determined by TSH \<0.5mIU/L during the screening period, anti-thyroid medication use, or hyperthyroidism diagnosis

Where it's running

  • University of California Irvine
    Orange, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.